Xenon Pharmaceuticals Inc
XENE Real Time Price USDRecent trades of XENE by members of U.S. Congress
|
Name
|
Type
|
Shares
|
Price
|
Shares Held
|
Date
|
Reported
|
|---|
|
Investor
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
|
Investor
|
Type
|
Shares
|
Change in Shares
|
Market Value
|
Date
|
Reported
|
|---|
Recently reported changes by institutional investors
Quarterly net insider trading by XENE's directors and management
* Insider trading data parsed from SEC Form 4 filings by Quiver Quantitative. Sign up for the Quiver API for real-time access.
- 1M
- 3M
- 6M
- YTD
- 1Y
- 2Y
- 5Y
- MAX
About
Key Metrics
Return (1d)
Return (30d)
Return (1Y)
CAGR (Total)
Max Drawdown
Beta
Alpha
Sharpe Ratio
Win Rate
Average Win
Average Loss
Annual Volatility
Annual Std Dev
Information Ratio
Treynor Ratio
Total Trades
Metrics Definitions
-
Alpha
Measures a portfolio's risk-adjusted performance against that of its benchmark
Learn More -
Annual Standard Deviation
Measures how much the portfolio's total return varies from its mean or average.
Learn More -
Annual Volatility
A statistical measure of the dispersion of returns for the portfolio.
Learn More -
Average Win
The average return (%) for trades that resulted in a positive return.
-
Average Loss
The average return (%) for trades that resulted in a negative return.
-
Beta
A measure of the volatility of the portfolio compared to the market as a whole.
Learn More -
CAGR
CAGR (Compounded Annual Growth Rate), is the historical annualized rate of return for an investment strategy, throughout the backtest period.
Learn More -
Information Ratio
A measurement of portfolio returns beyond the returns of its benchmark compared to the volatility of those returns.
Learn More -
Max Drawdown
the maximum observed loss from a peak to a trough of a portfolio, before a new peak is attained.
Learn More -
Sharpe Ratio
The Sharpe Ratio is a measure of historical risk-adjusted return, which quantifies the amount of return that an investor received per unit of risk.
Learn More -
Total Trades
The total number of trades made by this strategy.
-
Treynor Ratio
Attempts to measure how successful an investment is in providing compensation to investors for taking on investment risk.
Learn More -
Win Rate
The percentage of total trades that resulted in a positive return.
Be the first to see our newest insights and key updates across all datasets.
Government lobbying spending instances
Estimated quarterly lobbying spending
XENE Revenue by Segment or Geography
New patents grants
-
Patent Title: Methods of treating depressive disorders Dec. 31, 2024
-
Patent Title: Methods and uses for treating anhedonia Dec. 24, 2024
-
Patent Title: Pyridine derivatives and their use as sodium channel activators Aug. 06, 2024
-
Patent Title: Methods and uses for treating anhedonia Apr. 16, 2024
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents May. 10, 2022
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents Apr. 12, 2022
-
Patent Title: Benzenesulfonamide compouds and their use as therapeutic agents Nov. 16, 2021
-
Patent Title: Methods for enhancing the bio availability and exposure of a voltage-gated potassium channel opener Oct. 05, 2021
-
Patent Title: Solid state crystalline forms of a selective potassium channel modulator Aug. 17, 2021
-
Patent Title: Heteroaryl-substituted sulfonamide compounds and their use as therapeutic agents Apr. 20, 2021
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents Oct. 27, 2020
-
Patent Title: Heteroaryl-substituted sulfonamide compounds and their use as sodium channel inhibitors Aug. 25, 2020
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents Aug. 18, 2020
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents May. 26, 2020
-
Patent Title: Solid state forms of spiro-oxindole compounds Dec. 24, 2019
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents Apr. 02, 2019
-
Patent Title: Solid state forms of spiro-oxindole compounds Nov. 06, 2018
-
Patent Title: Asymmetric synthesis of funapide Oct. 16, 2018
-
Patent Title: Synthetic methods for spiro-oxindole compounds Jul. 04, 2017
-
Patent Title: Benzenesulfonamide compounds and their use as therapeutic agents Apr. 25, 2017
-
Patent Title: Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents Nov. 29, 2016
-
Patent Title: Asymmetric syntheses for spiro-oxindole compounds useful as therapeutic agents Nov. 08, 2016
-
Patent Title: Biaryl ether sulfonamides and their use as therapeutic agents Nov. 01, 2016
-
Patent Title: Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents Nov. 01, 2016
-
Patent Title: Spiro-oxindole compounds and their use as therapeutic agents Oct. 04, 2016
-
Patent Title: Biaryl ether sulfonamides and their use as therapeutic agents Jun. 14, 2016
-
Patent Title: Methods for identifying analgesic agents Mar. 08, 2016
-
Patent Title: Synthetic methods for spiro-oxindole compounds Feb. 16, 2016
-
Patent Title: N-substituted benzamides and methods of use thereof Feb. 10, 2015
-
Patent Title: N-substituted benzamides and methods of use thereof Jan. 13, 2015
-
Patent Title: Spiro-oxindole compounds and their use as therapeutic agents Dec. 23, 2014
-
Patent Title: Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents Nov. 11, 2014
-
Patent Title: Synthetic methods for spiro-oxindole compounds Jun. 03, 2014
-
Patent Title: Methods and reagents for modulating cholesterol levels May. 06, 2014
-
Patent Title: Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors Sep. 24, 2013
-
Patent Title: Juvenile hemochromatosis gene (hfe2a) cleavage products and uses thereof Aug. 13, 2013
-
Patent Title: Organic compounds Aug. 06, 2013
-
Patent Title: Use of spiro-oxindole compounds as therapeutic agents Jun. 18, 2013
-
Patent Title: Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents May. 28, 2013
-
Patent Title: Synthetic methods for spiro-oxindole compounds May. 21, 2013
-
Patent Title: Spiro-oxindole compounds and their uses as therapeutic agents Apr. 09, 2013
-
Patent Title: Methods for treating pain by inhibition of the scn9a channel Apr. 02, 2013
-
Patent Title: Pyridyl derivatives and their use as therapeutic agents Feb. 26, 2013
-
Patent Title: Spiro-oxindole compounds and their use as therapeutic agents Sep. 11, 2012
-
Patent Title: Juvenile hemochromatosis gene (hfe2a) cleavage products and uses thereof Aug. 28, 2012
-
Patent Title: Pyridyl derivatives and their use as therapeutic agents Apr. 10, 2012
-
Patent Title: Pyridazine derivatives and their use as inhibitors of stearoyl-coa desaturase-1 activity in a mammal Apr. 03, 2012
-
Patent Title: Spiro-oxindole compounds and their uses as therapeutic agents Jan. 31, 2012
-
Patent Title: Spiro-oxindole compounds and their use as therapeutic agents Jan. 24, 2012
-
Patent Title: Juvenile hemochromatosis gene (hfe2a), expression products and uses thereof Dec. 20, 2011
Federal grants, loans, and purchases
Estimated quarterly amount awarded from public contracts
Recent insights relating to XENE
Recent picks made for XENE stock on CNBC
ETFs with the largest estimated holdings in XENE
- ... Highest Price Target
- ... Median Price Target
- ... Lowest Price Target
|
Analyst
|
Firm
|
Current
|
Previous
|
Date
|
|---|
- Is $XENE stock a Buy, Sell, or Hold?
- What is the price target for $XENE stock?
* Analyst consensus is not financial advice. Please see our data disclaimers .
|
Shareholder
|
Shares Held
|
|---|
- Who owns $XENE stock?
- Who owns the most shares of $XENE stock?
- What funds own $XENE stock?
* These are estimates based on data taken from SEC filings. There may be inaccuracies due to parsing errors, accidental double-counting, incorrect classification of indirectly owned shares, or any other number of issues.
The Quiver Smart Score combines our data on Congress Trading, Lobbying, Insider Trading, CNBC Mentions and more to provide a comprehensive view of the strength of a stock's underlying data.
The Smart Score grades stocks on a scale of 1 (weakest) to 10 (strongest) based on the strength of the underlying data.Sign Up to view XENE Smart Score
See concise summaries of analyst reports, presenting both bullish and bearish arguments for a stock.
Example:
The Bulls Say summary highlights positive aspects of the stock.
The Bears Say summary points out potential risks and negative aspects of the stock.